Almost 70 percent with common breast cancer could skip chemo, study says

Breast cancer is the most common cancer in women worldwide; the World Cancer Research Fund International reported 1.7 million new cases in 2012. They are going to change treatment and remove uncertainty for women making decisions, ' Allison Kurian, an oncologist at Stanford University who was not involved in the trial said.

This year, about 260,000 new cases of breast cancer are expected in women in the United States, and 41,000 deaths.

Across the European Union, we have seen positive results for breast cancer care as more women are being diagnosed and treated earlier, leading to higher survival rates.

For the majority of women diagnosed with breast cancer in its early stages, chemotherapy is given for survival and to reduce recurrence of the breast cancer, but a study found that depending on the women's age and risk of getting cancer again, doing chemo doesn't have any benefit.

It is the first time this kind of approach has been successful in treating advanced breast cancer.

The TAILORx trial shows that only 30% of women with this particular form of early-stage breast cancer derive any benefit from the treatment.

"Now with these genomic tests, we are finding that we have multiple types of breast cancer, perhaps several dozen", Brawley said.

The TAILORx trial used the Oncotype DX test, now available on the NHS, which allows doctors to predict the likelihood of the breast cancer coming back.

The test examines 21 genes from a patient's breast cancer biopsy sample to determine how active they are.

Steel producer says USA customers already putting orders on hold amid tariffs
It's unclear what progress, if any, both sides made toward resolving the differences over purchases during the talks this weekend. China has threatened to hit back with tit-for-tat tariffs on tens of billions of dollars in U.S. goods.

North Korea state media says Syria’s Assad wants to meet Kim
It would be the first time the North Korean leader would be meeting the leader of a foreign country in a summit in Pyongyang. The North Korean delegation met with Trump to hand a letter from North Korean leader Kim Jong Un to the president.

Leroy Sane left out of Germany World Cup squad
Sane started the weekend loss to Austria, playing 67 minutes but failed to make an impact. Germany have announced their squad for the 2018 FIFA World Cup .

However, the response rate to even the most successful treatments is relatively low, with one recently trialled therapy showing strong effects in only around 10 per cent of prostate cancer patients.

Once a tumor is removed, 21 genes are analyzed and patients receive a low - intermediate - or high risk of reoccurrence.

But most women get an intermediate result meaning they are unclear as to what to do.

"Our study shows that chemotherapy may be avoided in about 70 percent of these women when its use is guided by the test, thus limiting chemotherapy to the 30 percent who we can predict will benefit from it", said lead researcher Dr Joseph A. Sparano, associate director for clinical research at the Albert Einstein Cancer Center and Montefiore Health System in NY.

The new research now exempts women with scores between 11 to 25 from chemotherapy as well, unless they are premenopausal.

Dr Simon Vincent, director of research at the charity Breast Cancer Now, warned more patients will have to be treated to assess how effective the therapy is. Simply put, the side effects are frightful: In addition to nausea, vomiting, hair and weight loss, chemo drugs can damage the heart and nervous system, and in rare cases, even cause different types of cancer.

"Breast cancer treatments have advanced so much that treatments can nearly be tailored for patients and this is extremely welcome news as chemotherapy is a particularly invasive treatment".

In addition, a recent study says chemo does not improve survival, that most women can be safely treated with just surgery and hormone blockers.

The trial results are the latest piece of the puzzle on how to treat early-stage breast cancer. Oncotype DX costs around $4,000, which Medicare and many insurers cover. Not only will they be able to dodge the side-effects of chemotherapy but they'll also feel more confident in their decision. The doctor said that her only hope of avoiding that toxic cocktail lay in the results of an ongoing trial, Tailorx. "So we have two yes-no answers for each gene. But it has only been shown to work in a single patient and we now need larger trials to investigate how the T-cell therapy and "checkpoint inhibitors" have worked together to attack the secondary tumours".

Related news:

Hot News